Introduction

Overview of apoptotic signaling
Programmed cell death (apoptosis) plays an important role in development, homeostasis and anticancer protection of multicellular organisms. Effective mechanisms for induction of programmed cell death in response to hormone-, immune-or stress-induced signaling are known to exist among most metazoan. Yet, it is the stochastic somatic cell mutations and epigenetic silencing of genes that regulate growth and death pathways, which play key roles in cancer development.
Apoptosis is characterized by distinct morphological and biochemical changes that take place upon the activation of a family of caspases, which are usually expressed as inactive zymogenes and require proteolytic processing upon initiation of apoptosis (Nicholson, 1999) . Two main apoptotic pathways result in activation of caspases. The first is induced upon the ligation of transmembrane death receptors with their cognate ligands, resulting in the activation of caspase-8 and -10, with concomitant activation of effector caspase-3 and -7. Six distinct death receptors are known and include TNF receptor-1 (TNF-R1), Fas (APO-1/CD95), TRAMP or death receptor-3 (DR3), TRAIL receptor-1 and receptor-2 (TRAIL-R1/DR4, TRAIL-R2/DR5) and death receptor-6 (DR6). Among these, TNF-R1, TRAIL, and Fas receptors and their ligands have been extensively investigated (Nagata, 1997 (Nagata, , 1999 Krammer, 2000; Daniel et al., 2001; Igney and Krammer, 2002; Johnstone et al., 2002) . Studies of the death-inducing signaling complex (DISC) revealed that trimerization of Fas and TRAIL receptors leads to recruitment of the Fas-associated death domain (FADD) , an adaptor molecule that recruits and activates caspase-8. In the case of TNF-R1 ligation, an additional adaptor molecule, TRADD, which binds TNF-R1 and FADD, is involved in formation of the death-induced signaling complex.
In the human body, Fas ligand (FasL) and TNFa are produced by activated lymphocytes and macrophages, respectively, whereas TRAIL is expressed by different cell types. In contrast, TNF-R1 and Fas receptors are widely expressed by normal cells whereas TRAIL receptors have more restricted distribution. Further, whereas the main function of Fas and TRAIL receptors is to induce the death-signaling pathway, TNF-R1's ability to elicit death signals is normally suppressed by NF-kB-dependent expression of antiapoptosis genes, and the TNF-R1/TRAF2/NF-kB/JNK/c-Jun signaling pathways (Baud and Karin, 2001) .
The second apoptosis network, which can be initiated by various forms of stress, requires caspase-2-dependent disruption of the mitochondrial membrane (Lassus et al., 2002) and release of mitochondrial proteins, including cytochrome c. Mitochondrial membrane permeabilization occurs as a result of altered balance between proapoptosis (BH3-only members of the Bcl-2 family, such as Bid or Bim) and antiapoptosis members of the Bcl-2 family (such as Bcl-2, Bcl-XL; Adams and Cory, 1998). Upon its release, cytochrome c cooperates with Apaf-1 to activate caspase-9, thereby initiating the amplification loop of the effector caspase cascade (Martinou and Green, 2001; Zamzami and Kroemer, 2001; Kumar and Vaux, 2002) . In certain conditions, crosstalk between the two apoptosis networks exist: Bid is cleaved by active caspase-8 following death receptor stimulation and translocates to the mitochondria, where it initiates the mitochondrial apoptosis pathway (Scaffidi et al., 1999; Johnstone et al., 2002) . Changes in availability of important components of this cascade were noted in the course of melanoma progression, as exemplified by the downregulation of Apaf-1 expression because of its hypermethylation in 40% of advanced melanomas (Soengas et al., 2001) . Mitochondrial pathways in melanoma apoptosis are reviewed by Soengas and Lowe in this issue.
Here, we focus on the key death signaling pathways and their regulation in the course of melanoma development. We further point to means that can be considered as targets for sensitizing resistant melanomas to therapy.
Altered signal transduction in melanoma: implication to death signaling cascades
The emerging picture, based on recent studies, suggests that signal transduction and the corresponding transcription factor effectors are among the key contributors to melanoma development and progression, based on the frequent changes found in the corresponding members of Ras and Raf signaling cascades. A high incidence of mutations within these pathways has been reported to exist in human melanomas. Whereas about 20% of melanomas appear to carry mutation in the N-ras oncogene (Herlyn and Satyamoorthy, 1996; Castellano and Parmiani, 1999) , over 60% were recently reported to contain mutation within the B-Raf gene (Davies et al., 2002) . In both cases, mutation renders both kinases constitutively active thereby eliciting constant signal towards the activation of downstream signaling components and the corresponding transcription factors substrates, including NF-kB, c-Jun and ATF2. Constitutively active Rac and ERKs, which correspond to the immediate target of Ras and B-Raf, respectively, were often seen in melanomas and other tumor types, and considered as target for therapy (Weinstein-Oppenheimer et al., 2000; Fan and Chambers, 2001; Hagemann and Blank, 2001; Herr and Debatin, 2001; Mandic et al., 2001) . Our former studies have demonstrated Rac1 ability to override PI3K signaling, which would otherwise result in upregulation of Fas surface expression . Similarly, the role of ERK in eliciting antiapoptotic signals has been well established (reviewed in Herr and Debatin, 2001; Hagemann and Blank, 2001) , thereby providing important insights into mechanisms underlying antiapoptotic signals in melanomas. Adding to these major impairments, the occurrence in PTEN mutation or epigenetic changes which inactivate PTEN, which renders PI3K constitutively active to elicit antiapoptotic signals (Zhou et al., 2000; Celebi et al., 2000) , strongly suggest that melanomas acquired the ability to attenuate signals that would normally lead to apoptosis, utilizes multiple pathways. Figure 1 highlights the impaired signaling cascades reported so far to exist in melanomas, and their downstream targets.
Transcription factors as master regulators of apoptosis cascades
Four families of transcription factors (NF-kB/Rel, AP1/ ATF2, Stat and p53) appear to serve as central regulators of cell's ability to commit towards apoptosis (Zhao et al., 2000; Darnell, 2002;  Shaulian and . Transcriptional output is highly dependent on the available factors and assembly of heterodimers or their proximal binding on specific promoters. Here, we describe three examples where the ability of melanoma to undergo apoptosis is directly dictated by the nature of some of the available transcriptional complex. Figure 2 highlights the major transcriptional players known to attenuate apoptosis in advanced melanomas.
Ras
Nuclear factor kB (NF-kB): the double sword factor As a sequence-specific transcription factor NF-kB coordinates expression of over 150 genes involved in regulation of inflammation, the immune response, cell proliferation and apoptosis. Of the five members of the NF-kB family in mammals (p50/p105, p52/p100, p65/ RelA, c-Rel and RelB), the prevalent form of NF-kB is the heterodimer of the p65/RelA and p50 subunits. Via its regulation of expression of proapoptosis and antiapoptosis genes, NF-kB is a key contribution to the balance between cell survival and apoptosis. In its antiapoptosis capacity, NF-kB attenuates TNFa-induced apoptosis (Beg and Baltimore, 1996) ; in this case NF-kB upregulates expression of c-IAP1, c-IAP2 (Deveraux et al., 1998) , TRAF-1, TRAF-2 (Baldwin, 1996), c-FLIP (Micheau et al., 2001) and BclxL genes , each of which has been shown to exert potent antiapoptosis effects. In contrast, NF-kB's ability to induce transcription of TNFR1 and TNFa (Baldwin, 1996) , TRAILR1, TRAILR2 and Fas (Chan et al., 1999; Ivanov and Ronai, 2000b; Zheng et al., 2001) are associated with its proapoptosis signals.
Suppression of NF-kB activity switches the prevailing death pathway in melanomas from FasL to TNFmediated apoptosis (Ivanov et al., 2001b) . Alternatively, TRAIL-induced apoptosis is suppressed by NF-kBdependent transcription in tumor cell lines , including melanomas (Franco et al., 2001 ), similar to NF-kB's effect on TNFa-induced apoptosis.
ATF2/c-Jun: transcriptional switch and melanoma resistance Early-phase-melanoma-derived cells have low basal yet inducible levels of AP-1 (Jun-Fos) activity. This activity markedly increases during tumor progression (Rutberg et al., 1994; Ivanov et al., 2000a) . Members of the AP-1 family, including c-Jun, have been implicated in controlling the balance between cell survival and death (Karin and Lin, 2002; Shaulian and Karin, 2002) .
Recent studies from our laboratory provide an example of ATF2/c-Jun-dependent transcription that dictates melanoma cells' resistance to apoptosis. ATF2 is a c-Jun heterodimer implicated in the regulation of Transcription factors implicated in attenuated death signaling in melanoma. Each of the three major apoptotic cascades is altered because of a different transcriptional switch. TNF signaling is affected by NF-kB, which can be upregulated either by elevated TRAF2 activity or constitutive ERK signaling because of mutated B-Raf. NF-kB in turn suppress caspases required for both TNFand Fas-mediated apoptosis, and inhibit Fas trafficking because of activation of FAP-1 that inhibits Fas export to the cell surface. Activation of TRAF2 and p38 result in the elevated ATF2 activity, which also elicits antiapoptotic signal. TRAIL, which is expressed at higher levels in advanced melanomas, is inhibited because of the elevated expression of decoy receptors that blocks TRAIL association with the receptor Death receptors and melanoma resistance to apoptosis VN Ivanov et al Jun2-bearing promoter sequences (van Dam et al., 1998; van Dam and Castellazzi, 2001) . ATF2 is upregulated in advanced melanomas, somewhat similar to what has been found for c-Jun (our own unpublished data). Inactivating ATF2 in melanoma-driven cell lines by the use of dominant-negative or transcriptionally inactive forms is sufficient to sensitize melanoma cells to treatment in vitro (Ronai et al., 1998) . Our search for an ATF2-derived peptide that may interfere with endogenous ATF2 function to enable sensitization of melanoma to apoptosis upon treatment led us to identify a 50 amino-acid (aa) sequence from the amino terminal ATF2 (aa 50-100) domain (Bhoumik et al., 2001) . Expression of this peptide not only sensitized melanoma cells to apoptosis in response to a wide range of treatments that otherwise do not affect this tumor type, but efficiently inhibited growth and metastasis in different mouse models in vivo (Bhoumik et al., 2002) . In evaluating the mechanism underlying the ATF2 peptide activities, we found that it efficiently inhibits ATF2's own function while causing marked increase in the activity of c-Jun. Increased c-Jun activity in the absence of ATF2 provides another microenvironment that suffices to sensitize melanoma (and other tumor types; our own unpublished data) to treatment. Inhibition of ATF2 per se results in increased activity of c-Jun in melanoma cells, highlighting the basic premise of this peptide activity. Consequently, the set of genes expressed has been altered, including the apoptosis pathway that has been switched towards the TRAIL pathway (Bhoumik et al., 2002) . In all, these findings highlight the importance of transcriptional regulation, which enables the sensitization of melanoma to treatment and inhibits their growth and metastasis in vivo.
p53; the tumor suppressor that may malfunction in melanoma The tumor suppressor protein p53 plays important role in the regulation of the mitochondrial apoptotic pathway by transcriptional activation of proapoptosis Bcl-2 family members (such as Bax, Bam, Puma and Noxa; reviewed in Bargonetti and Manfredi, 2002; Alarcon-Vargas and Ronai, 2002) and by repression of antiapoptosis Bcl-2 family proteins. p53 also promotes death receptor-mediated apoptosis by trans-activation of Fas and TRAIL-R2 transcription (Johnstone et al., 2002) . Although p53 is not mutated in the majority of human melanomas, evidence to support impaired transcriptional activities of p53 exists (Satyamoorthy et al., 2000) . An overall increase in p53 phosphorylation was observed in human melanomas, suggesting that it may result in the activation of a different subset of genes, when compared with nontransformed cells (Minamoto et al., 2001) . Further studies are required to define changes that may alter p53 function in advanced melanomas. (Nagata, 1999; Krammer, 2000) . However, in a large percentage of tumors Fas is not expressed appropriately, as reflected in fewer molecules per cell or a substantial decrease in the relative fraction of cells that express Fas on the cell surface (Igney and Krammer 2002; Reichmann, 2002) . Downregulation of Fas/CD95 in lymphoid and solid tumors is often associated with resistance to druginduced cell death (Muschen et al., 2000; Straus et al., 2001) . Similarly, human malignant melanomas that lack expression of Fas have a poor prognosis (Helmbach et al., 2001) . Of interest, whereas the Fas-apoptotic pathway is active in early-and intermediate-phase melanomas, it is often impaired in highly metastatic late-phase melanomas (Owen-Schaub et al., 1998; Chan et al., 1999; Bullani et al., 2002) . Inverse correlation between Fas expression and metastatic potential was also observed for osteosarcoma cells (Worth et al., 2002) . Downregulation of Fas signaling can be attributed to changes at the genomic, transcriptional and posttranslational levels. Mutations in the death domain of Fas have been reported to take place in 7% of metastatic melanomas (Shin et al., 1999) , resulting in an abnormal protein that exhibits abrogated association with FADD and procaspase-8, which are required for eliciting activation of downstream effector caspase-3. Somatic mutations in Fas, FADD and caspase 10 genes were also found in different hematopoietic malignancies (Kitada et al., 2002; Shin et al., 2002) .
Fas death cascade in melanoma
A more common event in melanomas relates to transcriptional downregulation of Fas expression. Silencing of Fas receptor promoter was reported to take place by cooperating transcription factors, as well as because of the hypermethylation of its promoter.
Regulation of Fas transcription has been shown to depend on NF-kB (Chan et al., 1999; Ivanov and Ronai, 2000b; Zheng et al., 2001 ), p53 (Owen-Schaub et al., 1995 and additional transcription factors such as Stat1 and Stat3. Common to these transcription factors is their positive effect on Fas receptor expression. However, cooperation of some, as shown for c-Jun and Stat3, results in suppression of Fas transcription. FasR promoter consists of three AP1-binding and three GAS elements, which provide the framework for Stat3 interaction with c-Jun, resulting in Fas suppression. Mutations within the promoter that abrogate the binding of either Stat3 or c-Jun are sufficient to increase Fas transcription. Fas expression could be rescued in melanomas that exhibit very low levels of Fas expression, by inhibition of Stat3 or c-Jun, thereby abrogating cooperation between the two oncogenes (Ivanov et al., 2001a) . Of interest, cooperation between Stat3 and c-Jun to silence Fas promoter is not limited to tumor cells, as fibroblasts that lack c-Jun or Stat3 also exhibited higher levels of Fas that could be suppressed upon re-expression of the lacking factor. Cooperation between Stat3 and c-Jun to suppress FasR transcription was found to depend on PI3K signaling. Inhibition of PI3K activities via the pharmacological inhibitor or dominant-negative forms of p85 or PKB was sufficient to increase transcriptional activities of Jun and Stat3, thereby resulting in decreased Fas transcription. PI3K negatively regulates Stat3 and c-Jun via its effect on intermediate kinases, including Rac1 pathway . Whereas in normal cells PI3K attenuates most of Stat3-Jun-mediated silencing, thereby enabling Fas transcription, in tumor cells this pathway is overridden because of the constitutive activities of downstream components including members of the Rac1, Rho and possibly Raf families because of activating mutation in Ras (reviewed in Herlyn and Satyamoorthy, 1996; Castellano and Parmiani, 1999) and B-Raf genes (Davies et al., 2002) .
Methylation of Fas promoter was also reported to take place in association with oncogenic Ras, resulting in lower levels of Fas transcripts (Peli et al., 1999) . A more recent study excluded a critical role of hypermethylation in the regulation of FasR expression (Santourlidis et al., 2001) .
Another means of attenuating Fas expression is its selective inhibition from expression on the cell surface. Certain melanomas exhibit appropriate expression of Fas, and yet this Fas is primarily localized within the cytoplasmic compartment of the cell, and thus cannot reach the cell surface, where it is required to function. Recent studies in our lab linked Fas-associated phosphatase-1 (FAP-1; Sato et al., 1995) to the regulation of Fas trafficking. Overexpression of FAP-1, which is often reported in human tumors, results in inhibition of Fas cell surface expression (Krasilnikov et al., 2003) .
Specific viral infection, as shown for adenovirus, is often accompanied by removal of Fas receptor from the cell membrane followed by its accelerated degradation, which is mediated by adenovirus E3 proteins (Tollefson et al., 1998; Elsing and Burgert, 1998) , thereby pointing to another mechanism that selectively targets Fas removal from the cell surface. Figure 3 highlights the components of the Fas cascades that were found to be altered in human tumors, resulting in efficient inactivation of the Fas death pathway.
A prerequisite to Fas death signaling is the availability of its ligand. FasL gene transcription is primarily seen in several types of normal cells in eyes, testis, and T lymphocytes (Nagata, 1999; Krammer, 2000) . However, stress, such as irradiation or DNA damage by different types of anticancer drugs, induces FasL transcription. The critical step in FasL induction is dependent on cJun activation by JNK, followed by c-Jun-dependent transcription via two AP-1 binding sites within the FasL-promoter (Zhang et al., 2000) . As a result, stressinduced expression of FasL can serve as the rate-limiting (Eichhorst et al., 2000; Kolbus et al., 2000; Kirchhoff et al., 2002) . FasL transcription is also regulated by NF-kB (Ivanov et al., 1997; Kasibhatla et al., 1998; Matsui et al., 1998; Hsu et al., 1999a, b; Li-Weber et al., 2000) , NF-AT (HoltzHeppelmann et al., 1998), EGR-3 (Mittelstadt and Ashwell, 1998) and SP1 (McClure et al., 1999) , transcription factors that are often upregulated in human tumors including melanomas. High levels of FasL expression by malignant melanomas has been implicated in suppression of the immune response during cancer progression (Hahne et al., 1996; O'Connell et al., 1999; Andreola et al., 2002) . Comparative studies of Fas and FasL expression revealed downregulation of Fas and upregulation of FasL expression during melanoma progression (Ekmekcioglu et al., 1999; Soubrane et al., 2000) . An inverse correlation between expression of FasL and that of Fas has been also found in melanoma-derived cell lines. Changing the balance between the ligand and the receptor so that both are expressed often resulted in efficient sensitization of the melanoma cells to apoptosis (Ivanov et al., 2001a . For example, transfection and overexpression of exogenous Fas in melanoma cells with high levels of endogenous FasL induced efficient cell death (Aragane et al., 2000) . Similarly, expression of exogenous FasL in tumor cells that express endogenous Fas receptor has often been tested as a possible anticancer treatment (Arai et al., 1997) . However, in vivo sensitization has been hampered because of the inability to target selectively the tumor cells, thereby causing an efficient apoptosis in nontransformed cells (Aoki et al., 2000) .
TRAIL and apoptosis in melanoma
When compared with nontransformed cells, cancer cells are more sensitive to TRAIL-induced apoptosis following exposure to TRAIL/Apo2 ligand treatment Marsters et al., 1999) . Selective sensitization of tumor cells to TRAIL-induced apoptosis can often be attributed to greater expression of the TRAIL receptor. Along these lines, cells that express high levels of TRAIL receptors, as shown for TRAIL-R2, are also highly sensitive to TRAIL-mediated cell death. The latter finding was confirmed in a large panel of cultured melanoma cells whose TRAIL receptor expression and TRAIL-dependent apoptosis were examined (Griffith et al., 1998; Zhang et al., 1999) . For this reason, TRAIL has been the preferred candidate for use in a therapeutic approach, given the distinct difference in its expression when compared with nontransformed cells. So far, treatment of melanomas (like other tumor types) with TRAIL-based therapy has yielded promising results (Thomas and Hersey, 1998; Ashkenazi et al., 1999; Walczak et al., 1999; Pollack et al., 2001) .
However, a large fraction of tumors, including melanomas, decrease expression or activities of TRAIL, resulting in attenuated TRAIL-dependent apoptosis.
Some melanoma cells have completely lost expression of TRAIL receptors, presumably as a result of loss of chromosome 8p22-21. In addition, loss of TRAIL receptor expression may also be attributed to an epigenetic silencing mechanism. Furthermore, at least two decoy receptors bind TRAIL without the ability to induce apoptosis, thereby pointing to an additional layer of regulation for the TRAIL apoptosis cascade (Krammer, 2000; Hersey and Zhang, 2001 ). Interestingly, some melanoma cell lines substantially increased basal levels of TRAIL expression upon expression of Stat3b, a dominant-negative form of Stat3 implying that Stat3 negatively regulates TRAIL transcription. Increased expression and secretion of TRAIL in Stat3b-transfected B16 mouse melanoma cells resulted in elevated apoptosis of these cells in vivo (Niu et al., 2001) . It is of interest that adenovirus infection results in the binding of adenoviral proteins to the TRAIL receptors resulting in their subsequent internalization and degradation (Tollefson et al., 2001) .
TNFa signaling in the regulation of apoptosis
A major apoptosis signaling pathway relies on TNFa and the network associated with TNFR-1 signaling. TNFa regulates inflammation, survival, proliferation and apoptosis by activating the membrane-bound receptors, TNF receptors 1 and 2 (TNFR) (Ashkenasi and Dixit 1998; Locksley et al., 2001; Chen and Goeddel, 2002) . Similar to Fas, TNF-R1 is trimerized upon the binding of its ligand, TNFa. Upon such binding there is efficient recruitment of adaptor protein TRADD and of TRAF2, which binds to NH 2 -terminal domain portion of TRADD (Hsu et al., 1996) and recruits the death effector domain (DED) proteins such as FADD and receptor interacting protein (RIP). FADD contains DED that binds to the DED of caspase-8, resulting in cleavage of procaspase-8 into its active form -caspase-8 and subsequent apoptosis (Hsu et al., 1996; Morgan et al., 2002) . However, unlike Fas, which mainly functions as stimulator of the apoptosis cascade, signaling from TNF-R1 often results in inhibition of apoptosis through the efficient activation of p38, IKK and NF-kB (Chen and Goeddel, 2002) . TNFR-1-mediated NF-kB activation results in activation of c-FLIP or cIAP, which efficiently inhibits caspase-8 activation (Baud and Karin, 2001; Micheau et al., 2001) , or of Bcl-xL, which attenuates cytochrome c release, thereby attenuating apoptosis that would have otherwise been elicited from the same receptor (Igney and Krammer, 2002) . The balance between the pro-and antiapoptotic signals within the TNF-R1 framework is central in dictating whether TNF-R1 activation results in TNF-dependent cell death (Figure 4) .
One of the important mediators of TNFR-1-dependent antiapoptosis signals is TRAF2, which is recruited to TNF-R1 via TRADD upon TNFa stimulation (Rothe et al., 1995; Chen and Goeddel, 2002) . TRAF2 in turn elicits activation of major stress-signaling cascades, resulting in activation, of NF-kB and NFkB-dependent expression of antiapoptosis proteins. In the absence of TRAF2-dependent NF-kB activation, TNFR1 will elicit efficient stimuli towards TRADD-FADD, and activation of caspases that result in efficient proapoptotic signals (Wajant et al., 2001; Chen and Goeddel, 2002) . Importantly, TRAF2-elicited signals are dependent upon its availability/stability, which is regulated by c-IAP-1 Siah2 (Habelhah et al., 2002) , RING-finger proteins with potent E3 ligase activity. Prolonged TRAF2 stability under stress conditions results in protection of cells from apoptosis, whereas accelerated degradation reduces antiapoptosis signaling, resulting in a higher fraction of cells that undergo apoptosis (Habelhah et al., 2002) . Consequently, owing to the nature of its stability, the availability of TRAF2 appears to play an important role in the regulation of the cell's ability to undergo apoptosis via TNF signaling.
It is of interest that progression of melanoma is often accompanied in a shift in cell's ability to undergo TNFmediated apoptosis. Whereas early-phase melanomas appear to utilize the TNF pathway, late-phase melanomas do not (Ivanov and Ronai, 1999) . Further, elevated TRAF2 expression has been often found in various human tumors, including melanomas (Devergne et al., 1996; Zapata et al., 2000; Murray et al., 2001) . The degree of TRAF2 expression following exposure of melanoma cells to treatment correlates with the degree of their resistance to apoptosis. Along these lines, expression of the dominant-negative form of TRAF2, which lacks its RING domain, suffices to sensitize melanoma cells to treatment (Ivanov et al., 2001b) . While further highlighting the importance of TRAF2 in regulating melanoma cells' ability to undergo apoptosis, these observations also imply that factors that play important roles in regulating TRAF2 stability and activity may undergo changes in the course of melanoma progression, explaining the impairment of TNFmediated cell death.
Inhibitors of apoptosis and FLIP
Inhibitors of apoptosis (IAPs) physically interact with a variety of proapoptosis proteins and stuppress apoptosis induced by different stimuli. Members of the IAP family are characterized by one to three tandem baculovirus IAP repeats (BIR); most also possess a carboxyl- terminal RING-finger motif (Miller, 1999) . The antiapoptosis activity of several IAPs is based on their ability to inhibit caspases. Human X-chromosomelinked IAP (X-IAP), for example, inhibits active caspase-3 and -7 and Apaf-1-cytochrome c-mediated activation of caspase-9. Common to melanomas is their upregulation of IAPs and downregulation of their effectors. For example, X-IAP is highly expressed in human melanomas . Via their RING-finger, IAPs serves as E3 ubiquitin ligases to promote the ubiquitination and proteasome-mediated degradation of the caspases that they bind (Yang et al., 2000; Suzuki et al., 2001) . ML-IAP is another member of this family, which is preferentially expressed in human melanomas (Vucic et al., 2000 (Vucic et al., , 2002 . IAPs are themselves regulated by proteins that suppress their antiapoptosis activity. For example, SMAC/DIABLO is processed during apoptosis into the active form and released from mitochondria to the cytosol, where it binds IAPs, preventing them from inhibiting caspases (Deveraux and Reed, 1999) . Another regulator of death receptor-mediated apoptosis that is often upregulated in melanomas is c-FLIP (FLICE-inhibitory protein), which serves as a negative inhibitor of caspase-8 (Irmler et al., 1997; Krueger et al., 2001; Thome and Tschopp, 2001) . In contrast, Apaf1, which is negatively regulated by IAPs, is silenced because of methylation in advanced melanomas (Soengas et al., 2001) . Transcription control of FLIP expression is dependent on NF-kB (Michaeu et al., 2001) , while proteasome-dependent degradation of FLIP may additionally sensitize cancer cells to TRAIL-mediated apoptosis .
Summary
Transcription factors appear to serve as the master regulators of apoptosis pathways. Therefore, their inactivation as a result of attenuated transcription or their activation because of altered post-translational modifications results in altered composition of their heterodimerization partners. Consequently, their ability to exert selective activation of a subset of genes associated with a specific phenotype, such as resistance to apoptosis, is modified. That key transcription factors such as NF-kB and c-Jun are able to exert both pro-and antiapoptosis functions provide strong support for the role of transcriptional switch as a primary factor in determining the nature of the apoptosis cascade and concomitant sensitization of melanoma cells to treatment. Examples provided in this review for mechanisms that govern Fas, TRAIL-receptors and TNF-receptors, three of the major apoptosis pathways, further support the importance of transcriptional regulation in determining which of the pathways will prevail and its functionality. This knowledge should allow design of better targets for treatment, which would enable selective modification of apoptotic cascade in specific tumor environments.
